Published in Med Decis Making on June 21, 2007
Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ (2008) 3.08
Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ (2011) 1.72
Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study. BMJ (2009) 1.20
Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer (2011) 1.16
Trade-offs in cervical cancer prevention: balancing benefits and risks. Arch Intern Med (2008) 1.15
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc (2008) 1.14
Progression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women. Infect Agent Cancer (2007) 0.88
Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine (2013) 0.87
Preferences for surveillance strategies for women treated for high-grade precancerous cervical lesions. Gynecol Oncol (2010) 0.83
Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Med (2009) 0.81
Percutaneous breast biopsy: effect on short-term quality of life. Radiology (2013) 0.80
Do clinical data and human papilloma virus genotype influence spontaneous regression in grade I cervical intraepithelial neoplasia? J Turk Ger Gynecol Assoc (2017) 0.78
Improving compliance with cervical cancer screening guidelines. Proc (Bayl Univ Med Cent) (2015) 0.78
Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. J Natl Cancer Inst (2016) 0.75
A survey of population-based utility scores for cervical cancer prevention. BMC Res Notes (2014) 0.75
Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada. BMC Health Serv Res (2016) 0.75
The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study. Cancer Causes Control (2016) 0.75
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med (2007) 7.31
The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst (2005) 6.03
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin (2012) 5.58
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol (2012) 3.51
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis (2012) 3.15
Forecasting the prevalence of pelvic floor disorders in U.S. Women: 2010 to 2050. Obstet Gynecol (2009) 3.08
Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol (2006) 3.08
Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst (2003) 3.08
Histological dating of timed endometrial biopsy tissue is not related to fertility status. Fertil Steril (2004) 3.03
Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med (2003) 2.72
The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis (2003) 2.72
Absence of secretory endometrium after false-positive home urine luteinizing hormone testing. Fertil Steril (2004) 2.59
Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol (2005) 2.50
Acute myocardial infarction in pregnancy: a United States population-based study. Circulation (2006) 2.49
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Predicting the number of women who will undergo incontinence and prolapse surgery, 2010 to 2050. Am J Obstet Gynecol (2011) 2.36
Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev (2013) 2.18
Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol (2013) 2.17
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Predictors of pregnancy in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 1.90
Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA (2003) 1.89
A prospective study of high-grade cervical neoplasia risk among human papillomavirus-infected women. J Natl Cancer Inst (2002) 1.83
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet (2002) 1.78
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol (2012) 1.78
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin (2009) 1.66
Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol (2004) 1.64
Comprehensive analysis of human leukocyte antigen class I alleles and cervical neoplasia in 3 epidemiologic studies. J Infect Dis (2002) 1.58
Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst (2006) 1.58
Risk of acute thromboembolic events with oral contraceptive use: a systematic review and meta-analysis. Obstet Gynecol (2013) 1.56
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects. Fertil Steril (2006) 1.56
Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control (2004) 1.54
Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer (2010) 1.53
FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol (2005) 1.52
Uterine artery embolization for treatment of leiomyomata: long-term outcomes from the FIBROID Registry. Obstet Gynecol (2008) 1.49
Nicotine replacement and behavioral therapy for smoking cessation in pregnancy. Am J Prev Med (2007) 1.44
Cost comparison of strategies for the management of venous thromboembolic event risk following laparotomy for ovarian cancer. Gynecol Oncol (2011) 1.44
HPV vaccines: now that they're here, how do we maximize their benefit? Contraception (2006) 1.41
The health care costs of cervical human papillomavirus--related disease. Am J Obstet Gynecol (2004) 1.39
Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol (2010) 1.37
A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control (2010) 1.35
Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. Obstet Gynecol (2010) 1.31
Fertility patients' views about frozen embryo disposition: results of a multi-institutional U.S. survey. Fertil Steril (2008) 1.30
Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab (2010) 1.29
Effect of hysterectomy with ovarian preservation on ovarian function. Obstet Gynecol (2011) 1.28
Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate (2003) 1.26
The FIBROID Registry: symptom and quality-of-life status 1 year after therapy. Obstet Gynecol (2005) 1.22
Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev (2004) 1.22
Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J Clin Microbiol (2007) 1.22
Adherence to nicotine replacement therapy among pregnant smokers. Nicotine Tob Res (2009) 1.21
Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol (2009) 1.16
Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization? Ann Pharmacother (2006) 1.15
Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J Clin Endocrinol Metab (2007) 1.14
Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol (2002) 1.14
Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis. Cost Eff Resour Alloc (2008) 1.14
Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol (2009) 1.12
Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol (2009) 1.10
Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer (2013) 1.10
Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests. Obstet Gynecol (2006) 1.09
Reducing ovarian cancer mortality through screening: Is it possible, and can we afford it? Gynecol Oncol (2008) 1.09
Management of adnexal mass. Evid Rep Technol Assess (Full Rep) (2006) 1.08
Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol (2009) 1.06
Comparison of documented and recalled histories of exposure to diagnostic x-rays in case-control studies of thyroid cancer. Am J Epidemiol (2003) 1.06
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol (2003) 1.05
PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res (2008) 1.05
Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNA-positive, cytologically negative women. Cancer (2002) 1.03
Challenges and solutions for recruiting pregnant smokers into a nicotine replacement therapy trial. Nicotine Tob Res (2006) 1.01
Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol (2011) 1.00
Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J Low Genit Tract Dis (2010) 0.99
Projecting the need for gynecologic oncologists for the next 40 years. Obstet Gynecol (2010) 0.99
Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies. Cancer (2008) 0.98
Semiquantitative human papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer Epidemiol Biomarkers Prev (2005) 0.97
Efficacy of screening in preventing cervical cancer among older women. Cancer Causes Control (2013) 0.97
Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol (2004) 0.97
Human papillomavirus prevalence in women who have and have not undergone hysterectomies. J Infect Dis (2006) 0.96
Cost-effectiveness analysis of annual screening strategies for endometrial cancer. Am J Obstet Gynecol (2009) 0.96
Reproducibility of biopsy diagnoses of endometrial hyperplasia: evidence supporting a simplified classification. Int J Gynecol Pathol (2008) 0.95
Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis (2002) 0.95